LES NYC Chapter Event
Planning for the future when negotiating a deal for biopharmaceutical intellectual property (IP).
Arnold Burstein, Executive Vice President, BioClara Group
Alan S. Paau, MBA, PhD, Vice Provost for Technology Transfer and Economic development, Cornell University
Jeffrey A. Wasserstein, Managing Director, Greenhill & Co
Charles A. Weiss, Partner, Holland & Knight
Negotiating for biopharmaceutical IP requires an understanding of its potential commercial value and, importantly, the future environment in which the IP will be commercialized. This includes anticipating market competition, generic inroads, new technologies/innovations, the opportunity to access future IP, maintaining an income stream, etc. It is often these ‘other’ issues that separate a successful deal from an unsuccessful one.
A distinguished panel of experts –representing both buyers and sellers – will discuss the implications of these (often considered) ‘secondary’ IP issues, how to quantify their potential impact, how to incorporate them into the negotiations, and how to establish metrics for evaluating their effect after the IP has been licensed.
Click here for online registration and more information.